Immunomedics to Report Third Quarter Fiscal 2018 Results and Host Conference Call and Webcast on May 9, 2018
May 02, 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it will host a conference call on Wednesday, May 9,...
Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
April 25, 2018 12:15 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug conjugates (ADCs), today announced...
Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer
April 09, 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., April 09, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug conjugates (ADCs), today announced...
Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference
March 05, 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLANS, N.J., March 05, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer,...
Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference
February 15, 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer,...
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
February 08, 2018 16:15 ET
|
Immunomedics, Inc.
Presented Compelling Results with Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (mTNBC) at San Antonio Breast Cancer Symposium Secured $250 Million Funding to Support Company’s...
Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018
February 06, 2018 08:00 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it will host a conference call on Thursday, February 8,...
Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer
January 11, 2018 08:00 ET
|
Immunomedics, Inc.
Immunomedics to Fund Phase 2 Study Sponsored by the University of Wisconsin to Enable Further Investigation of Sacituzumab Govitecan in the Treatment of Patients with Castration-Resistant Prostate...
Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million
January 08, 2018 08:30 ET
|
Immunomedics, Inc.
Royalty Pharma acquires Royalty Rights on Global Net Sales of Sacituzumab Govitecan (IMMU-132) Across All Indications for $175 Million Royalty Pharma Acquires $75 Million of Immunomedics Common Stock...
Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 04, 2018 08:45 ET
|
Immunomedics, Inc.
MORRIS PLAINS, N.J., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that Michael Pehl, President and Chief Executive Officer,...